We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-8.74%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.37B
AUM Growth
-$222M
Cap. Flow
+$490M
Cap. Flow %
20.72%
Top 10 Hldgs %
48.21%
Holding
122
New
26
Increased
34
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$66.1M
2
BDTX icon
Black Diamond Therapeutics
BDTX
+$51.6M
3
SDGR icon
Schrodinger
SDGR
+$33.9M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$30.5M
5
PYPL icon
PayPal
PYPL
+$26.5M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$37M
2
XNCR icon
Xencor
XNCR
+$18.9M
3
BNTX icon
BioNTech
BNTX
+$15.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11M
5
BABA icon
Alibaba
BABA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 69.19%
2 Consumer Discretionary 14.34%
3 Financials 1.8%
4 Technology 1.43%
5 Communication Services 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$251M 10.59%
14,818,300
– –
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$135M 5.7%
1,500,000
+300,000
+25% +$23.3M
BNTX icon
3
BioNTech
BNTX
$23.4B
$130M 5.5%
2,228,130
-400,000
-15% -$15.6M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$38.6B
$120M 5.06%
1,100,000
+100,000
+10% +$11.5M
LXRX icon
5
Lexicon Pharmaceuticals
LXRX
$1.03B
$117M 4.96%
60,240,864
– –
MRNA icon
6
Moderna
MRNA
$21.9B
$89.8M 3.8%
3,000,000
-1,606,298
-35% -$37M
ONC
7
BeOne Medicines Ltd
ONC
$34B
$80M 3.38%
650,000
+10,000
+2% +$1.56M
BABA icon
8
CALL
Alibaba
BABA
$275B
$77.8M 3.29%
+400,000
New +$83.5M
BABA icon
9
Alibaba
BABA
$275B
$77.8M 3.29%
400,000
-50,000
-11% -$10.4M
ARGX icon
10
argenx
ARGX
$55.4B
$62.6M 2.64%
475,000
+125,000
+36% +$18.3M
AVTR icon
11
Avantor
AVTR
$9.48B
$56.2M 2.38%
4,500,000
-250,000
-5% -$4.01M
QURE icon
12
uniQure
QURE
$2.73B
$54.6M 2.31%
+1,150,000
New +$66.1M
FATE icon
13
Fate Therapeutics
FATE
$267M
$46.6M 1.97%
2,100,000
+100,000
+5% +$2.53M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$46.2M 1.95%
5,000,000
+2,000,000
+67% +$19M
BAC icon
15
CALL
Bank of America
BAC
$435B
$42.5M 1.79%
+2,000,000
New +$60M
BDTX icon
16
Black Diamond Therapeutics
BDTX
$95.7M
$42.3M 1.79%
+1,696,517
New +$51.6M
PYPL icon
17
PayPal
PYPL
$50.4B
$42.1M 1.78%
440,000
+240,000
+120% +$26.5M
XBI icon
18
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$38.7M 1.64%
+500,000
New +$44.3M
SDGR icon
19
Schrodinger
SDGR
$1.12B
$38.7M 1.64%
+897,445
New +$33.9M
EPZM
20
DELISTED
Epizyme, Inc
EPZM
$35.7M 1.51%
2,300,000
+50,000
+2% +$1.07M
XLI icon
21
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$32.4B
$35.4M 1.5%
+600,000
New +$45.2M
DCPH
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$32.9M 1.39%
800,000
+550,000
+220% +$30.5M
Z icon
23
Zillow
Z
$7.81B
$32.4M 1.37%
900,000
+150,000
+20% +$6.93M
SRRK icon
24
Scholar Rock
SRRK
$5.95B
$30.8M 1.3%
2,546,040
– –
MORF
25
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$26.7M 1.13%
1,819,186
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2020 Portfolio in Review

As of Q1 2020, Artal Group held 122 positions worth $2.37B, down 8.6% from $2.59B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $490M of net new capital in Q1 2020, opening 26 new positions and adding to 34 existing holdings. Its largest new stake was uniQure: 1,150,000 shares worth $54.6M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 63% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Moderna, an estimated $37M trimmed.

  • Artal Group's largest Q1 2020 buy was uniQure: 1,150,000 shares worth $54.6M.
  • Artal Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $30.5M increase.
  • Artal Group's biggest Q1 2020 reduction was Moderna, cutting an estimated $37M.
  • Artal Group fully exited Xencor in Q1 2020, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 48% of its $2.37B portfolio in Q1 2020.
  • Artal Group opened 26 new positions and closed 19 in Q1 2020.
  • Artal Group's portfolio value fell 8.6% quarter-over-quarter to $2.37B.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.